179 related articles for article (PubMed ID: 8686737)
21. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240.
Wiman KG; Magnusson KP; Ramqvist T; Klein G
Oncogene; 1991 Sep; 6(9):1633-9. PubMed ID: 1923530
[TBL] [Abstract][Full Text] [Related]
23. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
[TBL] [Abstract][Full Text] [Related]
24. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
[TBL] [Abstract][Full Text] [Related]
25. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions.
Ihling C; Haendeler J; Menzel G; Hess RD; Fraedrich G; Schaefer HE; Zeiher AM
J Pathol; 1998 Jul; 185(3):303-12. PubMed ID: 9771485
[TBL] [Abstract][Full Text] [Related]
27. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.
Ungar S; Van de Meeren A; Tammilehto L; Linnainmaa K; Mattson K; Gerwin BI
Br J Cancer; 1996 Nov; 74(10):1534-40. PubMed ID: 8932331
[TBL] [Abstract][Full Text] [Related]
28. Analysis of glioma cell lines for amplification and overexpression of MDM2.
He J; Reifenberger G; Liu L; Collins VP; James CD
Genes Chromosomes Cancer; 1994 Oct; 11(2):91-6. PubMed ID: 7529554
[TBL] [Abstract][Full Text] [Related]
29. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
30. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.
Fernandez K; Serinagaoglu Y; Hammond S; Martin LT; Martin PT
Am J Pathol; 2010 Jan; 176(1):416-34. PubMed ID: 20019182
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors.
Iwato M; Tachibana O; Tohma Y; Nitta H; Hayashi Y; Yamashita J
Acta Neuropathol; 2000 Jan; 99(1):21-5. PubMed ID: 10651023
[TBL] [Abstract][Full Text] [Related]
32. Competitive reverse transcription/polymerase chain reaction for the quantification of p53 and mdm2 mRNA expression.
Totzke G; Sachinidis A; Vetter H; Ko Y
Mol Cell Probes; 1996 Dec; 10(6):427-33. PubMed ID: 9025080
[TBL] [Abstract][Full Text] [Related]
33. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.
Landers JE; Haines DS; Strauss JF; George DL
Oncogene; 1994 Sep; 9(9):2745-50. PubMed ID: 8058341
[TBL] [Abstract][Full Text] [Related]
34. Role of P53 and MDM2 in treatment response of human germ cell tumors.
Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2002 Mar; 20(6):1551-61. PubMed ID: 11896104
[TBL] [Abstract][Full Text] [Related]
35. Estradiol stabilizes p53 protein in breast cancer cell line, MCF-7.
Okumura N; Saji S; Eguchi H; Hayashi S; Saji S; Nakashima S
Jpn J Cancer Res; 2002 Aug; 93(8):867-73. PubMed ID: 12716463
[TBL] [Abstract][Full Text] [Related]
36. Results of p53 analysis in pediatric malignancies in Poland.
Fiszer-Maliszewska Ł; Czernik J; Sawicz-Birkowska K; Kazanowska B; Wojciechowska B
Med Pediatr Oncol; 2003 May; 40(5):316-21. PubMed ID: 12652620
[TBL] [Abstract][Full Text] [Related]
37. Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.
Preudhomme C; Quesnel B; Vachee A; Lepelley P; Collyn-D'Hooghe M; Wattel E; Fenaux P
Leukemia; 1993 Aug; 7(8):1291-3. PubMed ID: 8350630
[TBL] [Abstract][Full Text] [Related]
38. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas.
Nasir L; Rutteman GR; Reid SW; Schulze C; Argyle DJ
Cancer Lett; 2001 Dec; 174(1):83-9. PubMed ID: 11675155
[TBL] [Abstract][Full Text] [Related]
39. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
Foulkes WD; Stamp GW; Afzal S; Lalani N; McFarlane CP; Trowsdale J; Campbell IG
Br J Cancer; 1995 Oct; 72(4):883-8. PubMed ID: 7547235
[TBL] [Abstract][Full Text] [Related]
40. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
Gorgoulis VG; Zacharatos PV; Manolis E; Ikonomopoulos JA; Damalas A; Lamprinopoulos C; Rassidakis GZ; Zoumpourlis V; Kotsinas A; Rassidakis AN; Halazonetis TD; Kittas C
Br J Cancer; 1998; 77(3):374-84. PubMed ID: 9472631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
